Skip to main content

Table 1 Results of antimicrobial susceptibility testing of Raoultella planticola isolated strain

From: CTX-M-9 group ESBL-producing Raoultella planticola nosocomial infection: first report from sub-Saharan Africa

Name of antimicrobial substance

Kirby–Bauer disc diffusion testa

VITEK® 2 result

Diameter (mm)

EUCAST interpretation

MIC

EUCAST interpretation

Piperacillin

0

R

≥ 128

R

Piperacillin/tazobactam

21

S

8

S

Cefotaxime

0

R

8

R

Ceftazidime

22

S

≤ 1

S

Cefepime

22

I

≤ 1

S

Aztreonam

Not tested

 

2

I

Imipenem

26

S

0.5

S

Meropenem

27

S

≤ 0.25

S

Amikacin

20

S

≤ 2

S

Gentamicin

9

R

≥ 16

R

Tobramycin

12

R

8

R

Moxifloxacin

Not tested

 

2

R

Tigecycline

Not tested

 

1

S

Ciprofloxacin

17

R

1

R

Fosfomycin

Not tested

 

≤ 16

S

Colistin

Not tested

 

≤ 0.5

S

Trimethoprim/sulfamethoxazole

Not tested

 

≥ 320

R

  1. MIC minimum inhibitory concentration; R resistant, S sensitive, I intermediate
  2. aResults of antimicrobial susceptibility testing (AST) was done by using disc diffusion method at Asella, Ethiopia whereas VITEK was performed at institute of Medical Microbiology and Hospital Hygiene, Düsseldorf, Germany. Both results were interpreted by using European Committee on Antimicrobial Susceptibility Testing (EUCAST) version: 08.01